Oragenics Inc OGEN:NYSE American

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
2.34quote price arrow up+0.01 (+0.43%)
Volume
572,157
Close
2.33quote price arrow up+0.69 (+42.07%)
Volume
534,458
52 week range
1.00 - 7.74
Loading...
  • Open1.60
  • Day High2.40
  • Day Low1.60
  • Prev Close1.64
  • 52 Week High7.74
  • 52 Week High Date01/03/24
  • 52 Week Low1.00
  • 52 Week Low Date04/29/24

Key Stats

  • Market Cap10.44M
  • Shares Out4.48M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.51
  • YTD % Change-58.59

KEY STATS

  • Open1.60
  • Day High2.40
  • Day Low1.60
  • Prev Close1.64
  • 52 Week High7.74
  • 52 Week High Date01/03/24
  • 52 Week Low1.00
  • 52 Week Low Date04/29/24
  • Market Cap10.44M
  • Shares Out4.48M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.51
  • YTD % Change-58.59

RATIOS/PROFITABILITY

  • EPS (TTM)-8.69
  • P/E (TTM)-0.27
  • Fwd P/E (NTM)-0.20
  • EBITDA (TTM)-20.878M
  • ROE (TTM)-317.98%
  • Revenue (TTM)37,650.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-54,862.55%
  • Debt To Equity (MRQ)9.87%

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oragenics Inc

 

Profile

MORE
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an...
Charles Pope
Interim Executive Chairman of the Board
Michael Redmond
President, Interim Principal Executive Officer
Janet Huffman
Chief Financial Officer, Treasurer, Secretary
Address
1990 MAIN STREET, SUITE 750
Sarasota, FL
34236
United States

Top Peers

SYMBOLLASTCHG%CHG
IKT
Inhibikase Therapeutics Inc
1.73-0.03-1.70%
GOVX
GeoVax Labs Inc
1.70-0.04-2.30%
ATHE
Alterity Therapeutics Ltd
2.00-0.02-0.99%
ENVB
Enveric Biosciences Inc
0.84-0.06-6.6667%
HEPA
Hepion Pharmaceuticals Inc
1.30+0.06+4.84%